Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 9/20 | 0.42 |
| ▸ | CTSL | P07711 | 7/20 | 0.42 |
| ▸ | CTSS | P25774 | 7/20 | 0.42 |
| ▸ | CTSB | P07858 | 5/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | CCR6 | P51684 | 1/20 | 0.41 |
| ▸ | CTSV | O60911 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6206077 | 1.00 | CTSK (0.42) | CTSKCTSLCTSSCTSBALDH1A1 | |
| SCHEMBL6807048 | 0.80 | CTSK (0.42) | CTSKCTSLCTSSCTSBALDH1A1 | |
| SCHEMBL6807050 | 0.80 | CTSK (0.42) | CTSKCTSLCTSSCTSBALDH1A1 | |
| SCHEMBL4768241 | 0.78 | CTSK (0.45) | CTSKCTSLCTSSCTSBPKM | |
| SCHEMBL6629371 | 0.72 | CTSK (0.47) | CTSKCTSLCTSSCTSBPKM | |
| SCHEMBL14040701 | 0.71 | PKM (0.46) | CTSKCTSLCTSSCTSBALDH1A1 | |
| SCHEMBL6807052 | 0.71 | MMP13 (0.35) | CTSKALDH1A1SMN1; SMN2KDM4ELMNA | |
| SCHEMBL5105578 | 0.70 | CTSK (0.55) | CTSKCTSLCTSSCTSBCTSV | |
| SCHEMBL3921892 | 0.70 | KDM4E (0.58) | ALDH1A1SMN1; SMN2KDM4ELMNAPKM | |
| SCHEMBL14145059 | 0.70 | ALDH1A1 (0.41) | CTSKCTSLCTSSALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1401453-A4 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2005-04-06 | — | — | EP | disclosed |
| US-20040157828-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2004-08-12 | — | — | US | disclosed |
| EP-1401453-A2 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-03-31 | — | — | EP | disclosed |
| WO-2002092563-A2 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-11-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157828-A1 | Protease inhibitors | CTSK, MMP13, CTSZ | CTSK 1/4885CTSL 25/4885CTSS 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.